Company: RGBP
Filing Date: 2025-05-16
Form Type: 10-Q
Source: 0001641172-25-011206
Chunk: 23

Company: Regen BioPharma Inc
Filing Date: 2025-05-16
Form: 10-Q
Item: Part I, Item 1
Chunk 23
---
 equivalents      $                     (581      $            3,460  
  Cash, beginning of period                                                        716                 121,037  
  Cash, end of period                                       $                      135      $          124,497  

Operating
Activities

Net cash used in operating
activities for the quarter ended December 31, 2024 was $66,379, compared to $162,336, for the same period ended, 2023, a decrease of
$96,256. The decrease in cash used in operating activities is primarily attributable to decreased operating expenses incurred by the Company
during the quarter ended December 31, 2024 as compared to the same quarter ended 2023.

Financing Activities

Net cash generated by financing
activities for the quarter ended December 31, 2024 was $65,799 which consisted of proceeds from notes payables.

  23  

Liquidity & Capital
Resources Outlook

As of December 31, 2024,
the Company had cash of $ 135 and net working capital of ($5,696,776)

The Company has incurred
and expects to continue to incur significant professional costs to remain as a publicly traded company and it has incurred and expects
to continue incur significant research & development cost for products development.

The accompanying financial
statements have been prepared as if the Company will continue as a going concern. The Company has incurred significant operating losses
and negative cash flows from operations since inception. As of December 31, 2024, the Company had cash of approximately $135 and an accumulated
deficit of approximately $21 million. The Company has incurred recurring losses, experienced recurring negative operating cash flows,
and requires significant cash resources to execute its business plans. The Company is dependent on obtaining additional working capital
funding from the sale of equity and/or debt securities in order to continue to execute its development plans and continue operations.
Without additional funding, there is substantial doubt about the Company’s ability to continue as a going concern for the twelve
months from the date of these financial statements.

Contractual Obligations

As of December 31, 2024 the
Company was not party to any binding agreements which would commit Regen to any material capital expenditures.

Off-Balance Sheet Arrangements

We did not have any off-balance
sheet arrangements as defined in Item 303(a)(4)(ii) of Regulation S-K promulgated under the Exchange Act.

Item 3. Quantitative and
Qualitative Disclosures About